← All indications
Delayed Graft Function
General dysfunction of an organ occurring immediately following its transplantation. The term most frequently refers to renal dysfunction following KIDNEY TRANSPLANTATION.
Drugs by status
Phase 4 trials (5)
Phase 3 trials (9)
Phase 2 trials (9)
Phase 1 trials (2)
Other trials (3)
Organizations
Organization Involved with Phase 4 Indications (17)
- Bristol-Myers Squibb
- Roche
- Astellas
- Wyeth
- University of Pennsylvania
- Baylor University
- Instituto de Urologia e Nefrologia
- Loyola University
- Ochsner Health System
- University of Florida
- University of Maryland
- Mayo Clinic
- Columbia University
- University of Chicago
- Allegheny Health Network
- University of Nantes
- University of Wisconsin
Organization Involved with Phase 3 Indications (14)
- Alexion
- Angion Biomedica Corp
- Baxalta
- Prolong Pharmaceuticals
- Quark Pharmaceuticals
- Georgetown University
- University of Edinburgh
- University of Sydney
- University of Vienna
- University of Queensland
- CTI Clinical Trial and Consulting Services
- Government of Australia
- Health Research Council, New Zealand
- Kidney Research UK
Organization Involved with Phase 2 Indications (16)
- United Therapeutics
- Genzyme
- GlaxoSmithKline
- Opsona Therapeutics Ltd.
- Sponsor GmbH
- Y's Therapeutics, Inc.
- National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
- Heeger, Peter, M.D.
- Nair, Vinay, D.O.
- Schroppel, Bernd, M.D.
- Cedars-Sinai Medical Center
- Loma Linda University
- Rhode Island Hospital
- University of Rhode Island
- Icahn School of Medicine at Mount Sinai
- Dompe Pharmaceuticals
Organization Involved with Phase 1 Indications (4)
Organization Involved with Other Experimental Indications (3)